New AI system can help identify novel therapeutic targets implicated in various diseases

By | June 23, 2021
Insilico Medicine is pleased to announce that it has entered into a collaboration with Teva Branded Pharmaceutical Products R&D, Inc. to utilize Insilico’s generative machine learning technology and proprietary PandaOmics Drug Discovery Platform, which aims at identifying novel therapeutic targets implicated in a variety of diseases.